Contents 4 dk okuma

Claim and source comparison

Comparison scope: PubMed abstracts of Su 2003, MIDAS 2010, VITAL 2022, Cochrane 2021 and Gencer 2021; NIH ODS safety and product information. Not a full efficacy/safety review of every formulation.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human controlled trial; randomization not verified

Su 2003: In 28 patients with major depression, 6.6 g/day omega-3 added to usual treatment reduced depression scores more than placebo over eight weeks. This small double-blind trial proves neither monotherapy nor benefit in healthy people.

The accessed abstract does not explicitly verify randomization, so this is classified as a controlled human trial. The studied 6.6 g is not a personal recommendation or safe upper limit.

Source 2 · Abstract read

Human randomized controlled trial

MIDAS 2010: In 485 adults aged 55+ meeting age-related cognitive decline criteria, 900 mg/day DHA improved some learning and memory tests versus placebo at 24 weeks. Working-memory and executive-function tests did not differ.

Selected tests do not establish global cognitive rejuvenation or Alzheimer prevention. A DHA trial cannot be generalized to every EPA/DHA mixture or all brain functions.

Source 3 · Abstract read

Human randomized controlled trial

VITAL 2022: With 3424 participants assessed by phone and 794 in person, 1 g/day fish oil (840 mg EPA+DHA) showed no significant global cognitive benefit over 2–3 years. Pooled annual difference was −0.01 (95% CI −0.02–0.003; p=0.15).

Participants were generally healthy community-dwelling adults aged 60+. This null result for a product and follow-up is not a definitive judgment on every clinical group or lifelong dietary effect.

Source 6 · Abstract read

Systematic review / meta-analysis

Cochrane 2021: 34 placebo comparisons included 1924 people. Symptom analysis of 33 studies/1848 people found SMD −0.40 (95% CI −0.64–−0.16), with very low certainty. The average difference of about 2.5 HDRS points was below the review's 3-point clinical importance threshold.

Statistical difference is not certain clinical benefit. Heterogeneity, possible bias and confidence intervals matter. There were 35 studies overall; 1848 people belong only to the symptom meta-analysis.

Source 7 · Abstract read

Systematic review / meta-analysis

Gencer 2021 pooled 81,210 participants from seven randomized cardiovascular-outcome trials. Omega-3 was associated with higher atrial-fibrillation risk: HR 1.25 (95% CI 1.07–1.46). Relative increases were larger in trials using >1 g/day.

HR 1.25 is not an absolute increase of 25 percentage points. Between-trial dose comparisons do not define a personal safe threshold; the same magnitude cannot be assumed for every healthy user or formulation.

Source 8 · Abstract read

Official safety summary

NIH ODS: High doses may have antiplatelet effects, but most research in warfarin users found no significant change in anticoagulant status. This proves neither increased bleeding nor no risk for every product/drug pair; monitoring is assessed with the care team.

An antiplatelet mechanism alone does not quantify clinical bleeding. Nausea, reflux or diarrhea may occur; no frequency or guaranteed meal/coating prevention is given. Do not independently stop medicines or supplements before surgery.

Source 9 · Official summary read

Our evidence and source methodology

Omega-3 DHA/EPA: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What are Omega-3 DHA and EPA?

EPA and DHA are long-chain omega-3 fatty acids; DHA is an important brain membrane component. They are not a universal supplement treatment for depression or cognitive decline; clinical results vary by population and formulation.

ALA is the essential omega-3 fatty acid. Humans can synthesize small amounts of EPA and DHA from ALA, with limited conversion. DHA enters brain phospholipids, but it does not make up most brain fat and chronic deficiency cannot be assumed for everyone.

Clinical Trials

Su 2003: In 28 patients with major depression, 6.6 g/day omega-3 added to usual treatment reduced depression scores more than placebo over eight weeks. This small double-blind trial proves neither monotherapy nor benefit in healthy people.

The accessed abstract does not explicitly verify randomization, so this is classified as a controlled human trial. The studied 6.6 g is not a personal recommendation or safe upper limit.

MIDAS 2010: In 485 adults aged 55+ meeting age-related cognitive decline criteria, 900 mg/day DHA improved some learning and memory tests versus placebo at 24 weeks. Working-memory and executive-function tests did not differ.

Selected tests do not establish global cognitive rejuvenation or Alzheimer prevention. A DHA trial cannot be generalized to every EPA/DHA mixture or all brain functions.

VITAL 2022: With 3424 participants assessed by phone and 794 in person, 1 g/day fish oil (840 mg EPA+DHA) showed no significant global cognitive benefit over 2–3 years. Pooled annual difference was −0.01 (95% CI −0.02–0.003; p=0.15).

Participants were generally healthy community-dwelling adults aged 60+. This null result for a product and follow-up is not a definitive judgment on every clinical group or lifelong dietary effect.

Cochrane 2021: 34 placebo comparisons included 1924 people. Symptom analysis of 33 studies/1848 people found SMD −0.40 (95% CI −0.64–−0.16), with very low certainty. The average difference of about 2.5 HDRS points was below the review's 3-point clinical importance threshold.

Statistical difference is not certain clinical benefit. Heterogeneity, possible bias and confidence intervals matter. There were 35 studies overall; 1848 people belong only to the symptom meta-analysis.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

When reading the label of omega-3 supplements, the total amount of EPA + DHA should be checked; fish oil capsule weight can be much higher than this.

Safety and Side Effects

Gencer 2021 pooled 81,210 participants from seven randomized cardiovascular-outcome trials. Omega-3 was associated with higher atrial-fibrillation risk: HR 1.25 (95% CI 1.07–1.46). Relative increases were larger in trials using >1 g/day.

HR 1.25 is not an absolute increase of 25 percentage points. Between-trial dose comparisons do not define a personal safe threshold; the same magnitude cannot be assumed for every healthy user or formulation.

High-dose omega-3 is not risk-free for everyone. Large trials using 4 g/day in adults with cardiovascular disease or high risk found increased atrial fibrillation risk. Anticoagulants, pregnancy or surgery require medical review of dose and product.

NIH ODS: High doses may have antiplatelet effects, but most research in warfarin users found no significant change in anticoagulant status. This proves neither increased bleeding nor no risk for every product/drug pair; monitoring is assessed with the care team.

An antiplatelet mechanism alone does not quantify clinical bleeding. Nausea, reflux or diarrhea may occur; no frequency or guaranteed meal/coating prevention is given. Do not independently stop medicines or supplements before surgery.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Research and safety news

Sources

  1. Grosso G, et al. (2014). Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative Medicine and Cellular Longevity, 2014, 313570. PubMed · PMID 24757497
  2. Su KP, et al. (2003). Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology, 13(4), 267–271. PubMed · PMID 12888186
  3. Yurko-Mauro K, et al. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's & Dementia, 6(6), 456–464. PubMed · PMID 20434961
  4. Calder PC (2016). Docosahexaenoic acid. Annals of Nutrition and Metabolism, 69(Suppl 1), 7–21. PubMed · PMID 27842299
  5. Freeman MP, et al. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry, 67(12), 1954–1967. PubMed · PMID 17194275
  6. Kang JH, et al. (2022). Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. Alzheimer's & Dementia (New York, NY), 8(1), e12288. https://doi.org/10.1002/trc2.12288 PubMed · PMID 35415212
  7. Appleton KM, et al. (2021). Omega-3 fatty acids for depression in adults. The Cochrane database of systematic reviews, 11(11), CD004692. https://doi.org/10.1002/14651858.CD004692.pub5 PubMed · PMID 34817851
  8. Gencer B, et al. (2021). Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation, 144(25), 1981-1990. https://doi.org/10.1161/CIRCULATIONAHA.121.055654 PubMed · PMID 34612056
  9. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/ NIH Office of Dietary Supplements

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions